Anybody have any conjectures why Leo is releasing interim 6 week data in quarter 3 and not some preliminary partial like he did with the 19 patient Brilacidin-OM? It would be nice to see something first day of business in July.
Could it be IPIX is bound in a CDA with BPs for Prurisol 2B to only release 6 week interim data when X # of unblinded 12 or 16 week outcomes are accessible to Leo and whichever BPs have access to?
Could it be IPIX is bound in a CDA with BPs for Prurisol 2B to only release 6 week interim data when X # of unblinded 12 or 16 week outcomes are accessible to Leo and whichever BPs have access to?
1